# MSC EVs in Dystrophic Epidermolysis Bullosa

> **NCT04173650** · PHASE1,PHASE2 · RECRUITING · sponsor: **Aegle Therapeutics** · enrollment: 8 (estimated)

## Conditions studied

- Dystrophic Epidermolysis Bullosa

## Interventions

- **DRUG:** AGLE-102

## Key facts

- **NCT ID:** NCT04173650
- **Lead sponsor:** Aegle Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-13
- **Primary completion:** 2025-09
- **Final completion:** 2026-03
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04173650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04173650, "MSC EVs in Dystrophic Epidermolysis Bullosa". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04173650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*